scholarly journals Benefits from Long-Term Treatment in Irritable Bowel Syndrome

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Stefano Evangelista
Keyword(s):  
Clinical Trials ◽  
Irritable Bowel Syndrome ◽  
Term Treatment ◽  
Short Course ◽  
Long Term Treatment ◽  
Cyclic Treatment ◽  
Stopping Treatment ◽  
Irritable Bowel ◽  
Additional Value

It is known that irritable bowel syndrome (IBS) is a chronic disease of cyclic nature characterized by recurrent symptoms. IBS patients should receive, as initial therapeutic approach a short course of treatment which, if effective, has the additional value of confirming the diagnosis. Long-term treatment should be reserved to diagnosed IBS patients with recurrent symptoms. Clinical trials with stabilized therapies and new active treatments showed an improvement of the symptoms over placebo that is often time-dependent but with high relapse rates (around 40%–50% when stopping treatment). Relapse is not always immediate after stopping treatment and the recent data from OBIS trial with otilonium bromide or with psychotherapy, showed that due to different chemico-physical characteristics of the drugs or the psychosomatic impact to the disease not all treatment gave the same relapsing rate if compared to placebo. Results of IBS clinical trials with different therapies tailored to the patient needs indicate that a cyclic treatment therapy is advisable to counteract the nature of the disease.

Long-term treatment with probiotics in primary care patients with irritable bowel syndrome – a randomised, double-blind, placebo controlled trial

2013 ◽  
Vol 48 (10) ◽  
pp. 1127-1135 ◽  
Author(s):  
Luise Mølenberg Begtrup ◽  
Ove B Schaffalitzky de Muckadell ◽  
Jens Kjeldsen ◽  
René dePont Christensen ◽  
Dorte Ejg Jarbøl
Keyword(s):  
Primary Care ◽  
Irritable Bowel Syndrome ◽  
Controlled Trial ◽  
Term Treatment ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Long Term Treatment ◽  
Primary Care Patients ◽  
Irritable Bowel

Tegaserod: Long-Term Treatment for Irritable Bowel Syndrome Patients with Constipation in Primary Care

Digestion ◽  
2005 ◽  
Vol 71 (4) ◽  
pp. 238-244 ◽  
Author(s):  
Peter Layer ◽  
Jutta Keller ◽  
Stefan Mueller-Lissner ◽  
Peter Rüegg ◽  
Helena Loeffler
Keyword(s):  
Primary Care ◽  
Irritable Bowel Syndrome ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Irritable Bowel

A Case of Gastric Cancer in Which Long-Term Administration of 5′-Deoxy-5-Fluorouridine Proved Effective

1989 ◽  
Vol 17 (2) ◽  
pp. 179-184
Author(s):  
T. Koda ◽  
T. Kurahori ◽  
N. Iwao ◽  
S. Sumi ◽  
T. Sonoda ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Adverse Reactions ◽  
Substantial Improvement ◽  
Term Treatment ◽  
Borrmann Type ◽  
Long Term Treatment ◽  
Term Administration ◽  
Stopping Treatment ◽  
Lesser Curvature

A patient diagnosed with Borrmann type 4 gastric cancer (mucinous adenocarcinoma), who had refused surgery, was treated by oral administration of 1200 mg/day 5′-deoxy-5-fluorouridine for about 23 weeks. This resulted in substantial improvement of her condition, i.e. the tumour almost completely disappeared, distensibility improved between the central region of the corpus ventriculi and the angulus, and only small protrusions remained on the anterior and posterior walls and the pars pylorica of the lesser curvature. Mild anorexia and diarrhoea were noted as adverse reactions although these symptoms subsided by reducing the dose or temporarily stopping treatment, thereby allowing long-term treatment. Long-term use of 5′-deoxy-5-fluorouridine proved temporarily effective in this patient. The patient died about 3 years and 7 months after starting therapy. Examination showed that the cancer had been mainly in the stomach and that it had metastasized to the colon and pancreas. The liver was free of metastasis.

Sign in / Sign up

Export Citation Format

Share Document